Drug Type Monoclonal antibody |
Synonyms Anti STT-003 Ab, Anti-butyrophilin 1A1 mAb(STCube/MD Anderson Cancer Center) + [2] |
Target |
Action inhibitors |
Mechanism BTN1A1 inhibitors(butyrophilin subfamily 1 member A1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | United States | 01 May 2025 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | United States | 13 Feb 2024 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | South Korea | 13 Feb 2024 | |
Head and Neck Neoplasms | Phase 2 | South Korea | - | |
Head and Neck Neoplasms | Phase 2 | - | - | |
Lung Cancer | Phase 2 | South Korea | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | South Korea | 18 Apr 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 18 Apr 2022 |
Phase 1 | Colonic Cancer BTN1A1 | 47 | (all cohorts) | (wpqhfibifl) = ejevfmrsin rawagmsats (bkqrrujdfw ) View more | Positive | 23 Jan 2025 | |
(wpqhfibifl) = vrzxeantna rawagmsats (bkqrrujdfw ) View more |